We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
+6.36%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$6.76B
AUM Growth
-$342M
(-4.8%)
Cap. Flow
-$367M
Cap. Flow
% of AUM
-5.43%
Top 10 Holdings %
Top 10 Hldgs %
43.88%
Holding
93
New
7
Increased
14
Reduced
55
Closed
7
Top Buys
| 1 |
VERV
Verve Therapeutics
VERV
|
+$80.4M |
| 2 |
ZY
Zymergen Inc. Common Stock
ZY
|
+$60.1M |
| 3 |
SkinHealth Systems
SKIN
|
+$59.8M |
| 4 |
ONEM
1Life Healthcare
ONEM
|
+$41.7M |
| 5 |
Lifestance Health
LFST
|
+$33.2M |
Top Sells
| 1 |
Medtronic
MDT
|
+$116M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
+$96.2M |
| 3 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
+$85.8M |
| 4 |
Biogen
BIIB
|
+$45.6M |
| 5 |
Beam Therapeutics
BEAM
|
+$38.2M |
Sector Composition
| 1 | Healthcare | 95.41% |
| 2 | Consumer Staples | 1.58% |
| 3 | Financials | 0.69% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Fate Therapeutics
FATE
$336M
| $1.12B | 16.64% |
12,957,222
| – | – |
|
|
IGMS
2
DELISTED
IGM Biosciences
IGMS
| $285M | 4.22% |
3,425,455
| – | – |
|
|
3
Beam Therapeutics
BEAM
$3.13B
| $264M | 3.91% |
2,052,506
-480,017
| -19% | -$38.2M |
|
4
argenx
ARGX
$54.1B
| $238M | 3.52% |
790,282
-59,563
| -7% | -$16.9M |
|
|
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
| $201M | 2.97% |
20,799,303
-314,811
| -1% | -$3.07M |
|
|
ALLK
6
DELISTED
Allakos
ALLK
| $189M | 2.8% |
2,216,996
-202,422
| -8% | -$20.2M |
|
7
ADC Therapeutics
ADCT
$158M
| $183M | 2.71% |
7,522,029
+213,611
| +3% | +$4.96M |
|
8
Shattuck Labs
STTK
$605M
| $163M | 2.41% |
5,619,914
| – | – |
|
9
Replimune Group
REPL
$825M
| $161M | 2.38% |
4,191,512
+73,300
| +2% | +$2.51M |
|
|
NVTA
10
DELISTED
Invitae Corporation
NVTA
| $157M | 2.32% |
4,647,393
-204,770
| -4% | -$6.66M |
|
|
DCPH
11
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $155M | 2.3% |
4,244,721
-106,923
| -2% | -$4.14M |
|
12
Jazz Pharmaceuticals
JAZZ
$15.1B
| $153M | 2.26% |
860,101
+30,942
| +4% | +$5.36M |
|
|
MDVL
13
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
| $144M | 2.13% |
234,495
| – | – |
|
14
Krystal Biotech
KRYS
$10.2B
| $141M | 2.09% |
2,072,132
+12,000
| +0.6% | +$838K |
|
|
OSH
15
DELISTED
Oak Street Health, Inc.
OSH
| $135M | 2% |
2,302,653
-627,758
| -21% | -$37.4M |
|
16
Kymera Therapeutics
KYMR
$9.29B
| $123M | 1.82% |
2,531,508
-71,631
| -3% | -$3.11M |
|
|
SGEN
17
DELISTED
Seagen Inc. Common Stock
SGEN
| $122M | 1.8% |
771,385
-165,660
| -18% | -$24.6M |
|
|
VERV
18
DELISTED
Verve Therapeutics
VERV
| $117M | 1.73% |
+1,936,530
| New | +$80.4M |
|
|
19
SkinHealth Systems
SKIN
$119M
| $107M | 1.58% |
6,353,246
+4,370,497
| +220% | +$59.8M |
|
20
Celldex Therapeutics
CLDX
$3.01B
| $101M | 1.49% |
3,012,081
-375,707
| -11% | -$10.3M |
|
21
Atara Biotherapeutics
ATRA
$76.8M
| $100M | 1.48% |
257,983
-17,426
| -6% | -$6.22M |
|
|
NVRO
22
DELISTED
NEVRO CORP.
NVRO
| $98.6M | 1.46% |
594,732
+77,937
| +15% | +$12.2M |
|
23
DexCom
DXCM
$28.7B
| $98.4M | 1.46% |
922,232
+32,400
| +4% | +$3.11M |
|
24
LivaNova
LIVN
$4.41B
| $93.5M | 1.38% |
1,111,684
-8,146
| -0.7% | -$671K |
|
25
Pliant Therapeutics
PLRX
$68.7M
| $91.9M | 1.36% |
3,156,401
-50,792
| -2% | -$1.58M |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO